ACAA1 Is a Predictive Factor of Survival and Is Correlated With T Cell Infiltration in Non-Small Cell Lung Cancer

Frontiers in Oncology
Huiyi Feng, Weixi Shen

Abstract

Non-small cell lung cancer (NSCLC) is the predominant subtype of lung cancers. KRAS mutation is the second most prevalent mutation in NSCLC. KRAS mutant cancer cells suppress the anti-tumor T cell response. However, the underlying mechanism is still unknown. Here, we analyzed the differential expression of acetyl-CoA acyltransferase 1 (ACAA1) in various types of cancers using the TIMER database and validated the results in the NSCLC cell line H1944. We silenced oncogenic KRAS by siRNA targeting KRASG13D, and employed an MAPK signaling pathway inhibitor to clarify the possible regulatory pathway. Moreover, we analyzed the correlation of ACAA1 expression level with B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells. Correlations between expression of ACAA1 and several biomarkers of mutation burden were also tested. Finally, we evaluated the prognostic value of ACAA1 in a wide range of cancers using the Kaplan-Meier Plotter Database. We found lower expression of ACAA1 in tumor tissue than in adjacent normal tissue in various cancers. This result was confirmed using a GEO dataset. Knock-down of mutant KRAS resulted in increased ACAA1 mRNA level in H1944 cells. ACAA1 mRNA level was significantly upreg...Continue Reading

References

Apr 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Edward Y WooCarl H June
Oct 25, 2008·Nature·Li DingRichard K Wilson
Jul 25, 2015·Nature Reviews. Immunology·E John Wherry, Makoto Kurachi
Sep 12, 2015·Cell·Madhusudhanan SukumarNicholas P Restifo
Feb 18, 2016·Cancer Immunology Research·Stephanie ZdanovSamir N Khleif
Dec 14, 2016·The New England Journal of Medicine·Eric TranSteven A Rosenberg
Apr 13, 2017·Proceedings of the National Academy of Sciences of the United States of America·Arvin M GouwDean W Felsher
Apr 28, 2017·Frontiers in Oncology·Seema GuptaBilikere S Dwarakanath
May 12, 2017·Cancer Biology & Therapy·Shin SaitoHarmik J Soukiasian
Jul 25, 2017·Trends in Cell Biology·Costas A Lyssiotis, Alec C Kimmelman
Aug 18, 2017·JCI Insight·Tatiana AkimovaWayne W Hancock
Aug 25, 2017·Molecular Cancer Therapeutics·Aaron M GoodmanRazelle Kurzrock
Dec 22, 2017·Cancer Research·Patrícia Dias CarvalhoSérgia Velho
Mar 13, 2018·Frontiers in Immunology·Soumaya KouidhiAmel Benammar Elgaaied
Sep 5, 2018·Journal of Experimental & Clinical Cancer Research : CR·Zeribe C NwosuSteven Dooley
Nov 1, 2018·British Journal of Cancer·Francesco PassigliaDomenico Galetta
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 12, 2019·The Journal of Pathology·Thijs S StutvoetSteven de Jong
Aug 14, 2019·Cancer Cell International·Francesca GaluppiniRaffaele Baffa
Sep 15, 2019·Journal of Experimental & Clinical Cancer Research : CR·Zhongping YinJiuwei Cui
Dec 19, 2019·Cancers·Patrícia Dias CarvalhoSérgia Velho

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-seq

Software Mentioned

GEPIA
TIMER

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.